Pursuant to the provisions of article 226 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

INSIDE INFORMATION

Following the Relevant Events dated 13 November 2019, 7 March 2019 and 21 November 2018, Grifols informs that, all legal requirements requested by the People’s Republic of China and the United States for the closing of the transaction between Shanghai RAAS Blood Products Co. Ltd. ("SR"), a company listed in the Shenzhen Stock Exchange, and Grifols have been consummated. The shares Grifols so acquires will be listed on Shenzhen Stock Exchange during next week.

Grifols will hold 26.2% voting and economic rights in SR. In exchange, Grifols has contributed 45% economic rights in its US subsidiary, Grifols Diagnostic Solutions Inc. ("GDS"), and 40% voting rights in GDS.

Once the swap of shares has taken place, Grifols will continue to hold 55% economic rights and 60% voting rights in GDS.

The main shareholders in SR will be Grifols with ca. 26.2%, followed by Creat Group Co. Ltd with ca. 26.18% and RAAS China Limited with ca. 22.78%. Other minority and institutional investors will hold the remaining shares.

- Based on the current shareholding structure of SR, Grifols has the right to nominate three directors in SR and SR has the right to nominate two directors in GDS.

- Based on the current shareholding structure of SR, Grifols has a veto right on certain decisions such as issue of shares, disposal of major assets, mergers and modification of the articles of association, including anti-dilution clauses to protect Grifols’ stake. To this end, reinforced quorum has been included in SR’s articles of association.

- Creat has agreed not to sell its stake in SR to a competitor of Grifols and Grifols will not be able to sell its stake in GDS to any Chinese citizen, legal entity or other organization (except with SR’s prior written consent).

Moreover, Grifols and SR have entered into an Exclusive Strategic Alliance Agreement, which sets up the international manufacturing and quality standards SR needs to meet. Grifols will appoint a quality person to provide advice on and follow compliance with such agreed quality standards.

SR will be the exclusive distributor of the bioscience and diagnostic products of Grifols in China. In exchange of royalties, Grifols will provide technological and know-how support in bioscience and diagnostic fields to SR for use in China. Grifols will also provide engineering services to SR in exchange of fees. SR commits to use GDS NAT technology in its plasma collection businesses.

This transaction reinforces Grifols’ sustained growth strategy and long-term vision.

In Barcelona, on 27 March 2020

Nuria Martín Barnés
Secretary to the Board of Directors